DaRT radiation plus chemo for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new type of radiation called DaRT (Alpha DaRT) combined with standard chemotherapy for people with pancreatic cancer that is locally advanced or has spread. The goal is to see if adding this radiation treatment can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been newly diagnosed with pancreatic cancer that is either locally advanced (cannot be removed with surgery) or has spread to other parts of the body (metastatic).
- Before starting the radiation treatment (DaRT), you need to first receive 1 to 4 cycles of a chemotherapy regimen called mFOLFIRINOX.
- The tumor being treated must be small enough (5 cm or less) and located in a spot where doctors can safely place the radiation seeds.
- You must be in generally good health, able to care for yourself (ECOG performance status 0-2), and have a life expectancy of at least 6 months.
- You must have adequate kidney and liver function, and your blood counts need to be high enough to safely receive treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called DaRT, which places tiny radioactive devices directly into your pancreatic tumor. It is for people with locally advanced pancreatic cancer that has not spread, after they have already had standard chemotherapy.
This trial tests a new treatment that uses tiny alpha radiation sources placed directly into the tumor to destroy cancer cells. It is for people with pancreatic cancer that has not spread but cannot be removed surgically, and who have already tried at least one type of chemotherapy or cannot take more chemo.
This trial tests a radiation treatment that places tiny radioactive seeds directly into the tumor to treat advanced pancreatic cancer. It mainly focuses on safety and whether the treatment can be delivered effectively, especially for people who may not be able to have more chemotherapy or surgery.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
This trial tests whether giving targeted radiation (SBRT) followed by an experimental immunotherapy drug injected directly into the tumor is safe for people with locally advanced pancreatic cancer. It aims to shrink the tumor and help your immune system fight it.
This study tests a highly focused radiation plan that uses MRI scans to adjust treatment during therapy. It’s for people with locally advanced pancreatic cancer who have already completed a set course of chemotherapy and whose cancer hasn’t grown.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.